Arovella Therapeutics Ltd

ALA

Company Profile

  • Business description

    Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

  • Contact

    84 Hotham Street
    Corporate One
    PrestonVIC3072
    AUS

    T: +61 398636472

    https://www.arovella.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    44

Stocks News & Analysis

stocks

Here’s how to value a share

Our best resources to help investors determine the value of a share.
stocks

How to avoid dividend disaster

Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks

GyG punished by market after solid earnings

Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,245.0066.30-0.71%
CAC 407,843.04126.65-1.59%
DAX 4024,273.1289.97-0.37%
Dow JONES (US)45,388.41243.33-0.53%
FTSE 1009,321.4012.200.13%
HKSE25,829.91490.771.94%
NASDAQ21,537.1640.630.19%
Nikkei 22542,807.82174.530.41%
NZX 50 Index13,079.5036.740.28%
S&P 5006,460.266.65-0.10%
S&P/ASX 2008,972.4071.70-0.79%
SSE Composite Index3,883.5657.801.51%

Market Movers